DOXORUBICIN-INDUCED CROSS-RESISTANCE TO TUMOR-NECROSIS-FACTOR (TNF) RELATED TO DIFFERENTIAL TNF PROCESSING

被引:16
作者
FRUEHAUF, JP
MIMNAUGH, EG
SINHA, BK
机构
[1] Biochemical and Molecular Pharmacology Section, Clinical Pharmacology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
来源
JOURNAL OF IMMUNOTHERAPY | 1991年 / 10卷 / 03期
关键词
TUMOR NECROSIS FACTOR; DRUG RESISTANCE; RECEPTOR PROCESSING;
D O I
10.1097/00002371-199106000-00002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate whether cells selected for doxorubicin resistance were cross-resistant to tumor necrosis factor, the effects of doxorubicin and recombinant human tumor necrosis factor-alpha (TNF) on doxorubicin-sensitive (WT) and 40-fold doxorubicin-resistant (40F) MCF-7 cell proliferation were assessed. The median dose (MD) for doxorubicin was 14.5 nM for WT cells and 474 nM for 40F cells. The MD for TNF was 0.18 nM for WT cells, while 40F cells were highly resistant to TNF concentrations up to 60 nM. Doxorubicin and TNF in combination were synergistic against WT cells, but not 40F cells. Glutathione depletion by buthionine sulfoxamine sensitized WT cells threefold to TNF, with no change in their response to doxorubicin, while 40F cells showed a twofold increase in doxorubicin sensitivity, with no apparent change in their resistance to TNF. No significant differences in TNF receptor number, K(d), or capacity for TNF internalization were noted between the two cell types. WT cells produced a single 15 kDa TNF degradation product, while the 40F cells produced three lower molecular weight degradation products. We conclude that cross-resistance to TNF in doxorubicin-resistant MCF-7 cells may be explained in part by altered TNF degradation.
引用
收藏
页码:165 / 173
页数:9
相关论文
共 56 条
[11]  
BECK WT, 1987, BIOCHEM PHARMACOL, V36, P1879
[12]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[13]   CYTO-TOXICITY MEDIATED BY TUMOR NECROSIS FACTOR IN VARIANT SUBCLONES OF THE ME-180 CERVICAL-CARCINOMA LINE - MODULATION BY SPECIFIC INHIBITORS OF DNA TOPOISOMERASE-II [J].
COFFMAN, FD ;
GREEN, LM ;
GODWIN, A ;
WARE, CF .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1989, 39 (02) :95-105
[14]  
COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9318
[15]   A HIGH-MOLECULAR-WEIGHT COMPONENT OF THE HUMAN-TUMOR NECROSIS FACTOR RECEPTOR IS ASSOCIATED WITH CYTOTOXICITY [J].
CREASEY, AA ;
YAMAMOTO, R ;
VITT, CR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (10) :3293-3297
[17]   SPECIFICITY OF TUMOR NECROSIS FACTOR TOXICITY FOR HUMAN MAMMARY CARCINOMAS RELATIVE TO NORMAL MAMMARY EPITHELIUM AND CORRELATION WITH RESPONSE TO DOXORUBICIN [J].
DOLLBAUM, C ;
CREASEY, AA ;
DAIRKEE, SH ;
HILLER, AJ ;
RUDOLPH, AR ;
LIN, L ;
VITT, C ;
SMITH, HS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4740-4744
[18]  
DUSRE L, 1989, CANCER RES, V49, P519
[19]   SYNERGISTIC ACTIVITY OF SURAMIN WITH TUMOR NECROSIS FACTOR-ALPHA AND DOXORUBICIN ON HUMAN PROSTATE-CANCER CELL-LINES [J].
FRUEHAUF, JP ;
MYERS, CE ;
SINHA, BK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (14) :1206-1209
[20]   EFFECT OF ERYTHROMYCIN AND TUMOR NECROSIS FACTOR ON THE DRUG-RESISTANCE OF MULTIDRUG-RESISTANT CELLS - REVERSAL OF DRUG-RESISTANCE BY ERYTHROMYCIN [J].
HOFSLI, E ;
NISSENMEYER, J .
INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (03) :520-525